Opinion|Videos|April 1, 2026
Sequencing Factors in Later-Line Follicular Lymphoma
Author(s)Loretta J. Nastoupil, MD, Amitkumar Mehta, MD
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss factors that can inform sequencing planning in follicular lymphoma management.
Advertisement
Episodes in this series
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, explore broader sequencing strategies for patients with relapsed/refractory follicular lymphoma. Nastoupil emphasizes how toxicity profiles, treatment setting, and patient preferences influence the order of therapies. Mehta adds that integrating newer agents requires careful planning to preserve future treatment options, including cellular therapies.
Advertisement
Related to this article
An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.
Roswell Park researchers showed that blocking a novel metabolic pathway severely restricts tumor proliferation.
Dostarlimab monotherapy met the primary end point of sustained clinical complete response at 12 months in the phase 2 AZUR-1 trial.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
The decision does not reflect new concerns about the clinical efficacy or safety data from the phase 3 CARES-310 trial.
The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
Mark Garzotto, MD, discusses data with aglatimagene besadenovec plus valacyclovir and EBRT in intermediate- to high-risk localized prostate cancer.
Rocbrutinib elicited an overall response rate of 63.9% in covalent BTK inhibitor–pretreated relapsed/refractory mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma
2
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
3
Rocbrutinib Displays Durable Activity in Covalent BTK Inhibitor–Pretreated R/R MCL
4
Dive Into Key Data and Presentations From EHA 2026
5